Compass Therapeutics shed half its stock price this morning as investors digested its bispecific antibody’s failure to hit an ...

Compass Therapeutics said its cancer treatment improved progression-free survival in a recent trial, but didn't meet its secondary endpoint in overall survival. Shares fell 23% to $3.85 in premarket ...

Compass Therapeutics Inc. CMPX shares are tumbling on Monday as the company announced results from its COMPANION-002 study, ...

While tovecimig met the main goal of progression-free survival in a Phase 2/3 trial, it did not improve overall survival.

The FDA is awarding national priority vouchers to Compass Pathways and the Usona Institute as the Trump administration looks ...

Compass Pathways may be the first to benefit from an accelerated approval process.